Literature DB >> 29474196

Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.

Girish Kumar Parida1, Sarthak Tripathy, Shreya Datta Gupta, Abhinav Singhal, Rakesh Kumar, Chandrasekhar Bal, Shamim Ahmed Shamim.   

Abstract

Ga-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like Ga-DOTANOC PET/CT and F-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of Ga-PSMA PET/CT imaging and benefit of Ga-DOTANOC PET/CT and F-FDG PET/CT in such cases.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29474196     DOI： 10.1097/RLU.0000000000002013

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  14 in total

1.  Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT.

Authors:  Ruohua Chen; Yining Wang; Yiping Shi; Yinjie Zhu; Lian Xu; Gang Huang; Jianjun Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-02       Impact factor: 9.236

2.  GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.

Authors:  Salma Meziou; Cassandra Ringuette Goulet; Hélène Hovington; Véronique Lefebvre; Étienne Lavallée; Michelle Bergeron; Hervé Brisson; Audrey Champagne; Bertrand Neveu; Didier Lacombe; Jean-Mathieu Beauregard; François-Alexandre Buteau; Julie Riopel; Frédéric Pouliot
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-01-13       Impact factor: 5.554

3.  Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms.

Authors:  Jingliang Zhang; Shuai Shao; Peng Wu; Daliang Liu; Bo Yang; Donghui Han; Yu Li; Xiaoyu Lin; Wei Song; Milin Cao; Jing Zhang; Fei Kang; Weijun Qin; Jing Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-11       Impact factor: 9.236

4.  Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.

Authors:  Joel Vargas Ahumada; Sofía D González Rueda; Fabio A Sinisterra Solís; Quetzali Pitalúa Cortés; Liliana P Torres Agredo; Jimenez Ríos Miguel; Anna Scavuzzo; Irma Soldevilla-Gallardo; Miguel A Álvarez Avitia; Nora Sobrevilla; Francisco Osvaldo García Pérez
Journal:  Diagnostics (Basel)       Date:  2022-06-03

5.  The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.

Authors:  Ruohua Chen; Yining Wang; Yinjie Zhu; Yiping Shi; Lian Xu; Gang Huang; Jianjun Liu
Journal:  J Nucl Med       Date:  2022-01       Impact factor: 11.082

6.  Obstructive Jaundice: An Unusual Presentation of Neuroendocrine Differentiation in Prostatic Adenocarcinoma.

Authors:  Sampath Santhosh; Godwin Jeeva; Ranjan Kumar Mohapatra
Journal:  Indian J Nucl Med       Date:  2021-03-04

7.  The Heterogeneous Metabolic Patterns of Ganglia in 68Ga-PSMA, 11C-choline, and 18F-FDG PET/CT in Prostate Cancer Patients.

Authors:  Yiping Shi; Jian Guo Wu; Lian Xu; Yinjie Zhu; Yining Wang; Gan Huang; Jianjun Liu; Ruohua Chen
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

8.  Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for 18F-FDG Imaging of PSMA-Suppressed Tumors.

Authors:  Martin K Bakht; Jessica M Lovnicki; Janice Tubman; Keith F Stringer; Jonathan Chiaramonte; Michael R Reynolds; Iulian Derecichei; Rosa-Maria Ferraiuolo; Bre-Anne Fifield; Dorota Lubanska; So Won Oh; Gi Jeong Cheon; Cheol Kwak; Chang Wook Jeong; Keon Wook Kang; John F Trant; Colm Morrissey; Ilsa M Coleman; Yuzhuo Wang; Hojjat Ahmadzadehfar; Xuesen Dong; Lisa A Porter
Journal:  J Nucl Med       Date:  2019-12-05       Impact factor: 11.082

9.  Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.

Authors:  Florian Rosar; Kalle Ribbat; Martin Ries; Johannes Linxweiler; Mark Bartholomä; Stephan Maus; Mathias Schreckenberger; Samer Ezziddin; Fadi Khreish
Journal:  EJNMMI Res       Date:  2020-05-24       Impact factor: 3.138

Review 10.  More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Authors:  Anniina Hyväkkä; Verneri Virtanen; Jukka Kemppainen; Tove J Grönroos; Heikki Minn; Maria Sundvall
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.